Oncology Institute Inc (TOI) - Net Assets
Based on the latest financial reports, Oncology Institute Inc (TOI) has net assets worth $-16.29 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($168.23 Million) and total liabilities ($184.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Oncology Institute Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-16.29 Million |
| % of Total Assets | -9.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -115.09% |
| 10-Year Change | N/A |
| Growth Volatility | 239.8 |
Oncology Institute Inc - Net Assets Trend (2019–2025)
This chart illustrates how Oncology Institute Inc's net assets have evolved over time, based on quarterly financial data. See Oncology Institute Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Oncology Institute Inc (2019–2025)
The table below shows the annual net assets of Oncology Institute Inc from 2019 to 2025. For live valuation and market cap data, see Oncology Institute Inc (TOI) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-15.72 Million | -538.01% |
| 2024-12-31 | $3.59 Million | -93.71% |
| 2023-12-31 | $57.02 Million | -53.70% |
| 2022-12-31 | $123.17 Million | +18.26% |
| 2021-12-31 | $104.16 Million | +270.66% |
| 2020-12-31 | $28.10 Million | -33.45% |
| 2019-12-31 | $42.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncology Institute Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26540397700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | % |
| Other Components | $255.69 Million | % |
| Total Equity | $-15.72 Million | 100.00% |
Oncology Institute Inc Competitors by Market Cap
The table below lists competitors of Oncology Institute Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhengzhou Tiamaes Technology Co Ltd
SHE:300807
|
$400.94 Million |
|
Suzhou Industrial Park Heshun Electric Co Ltd
SHE:300141
|
$401.08 Million |
|
Panoro Energy ASA
OL:PEN
|
$401.14 Million |
|
Renxin New Material Co. Ltd. A
SHE:301395
|
$401.21 Million |
|
Melcor Developments Ltd.
TO:MRD
|
$400.77 Million |
|
Dongbu Steel Co Ltd
KO:016380
|
$400.74 Million |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
$400.66 Million |
|
Tubacex S.A
MC:TUB
|
$400.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncology Institute Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,589,000 to -15,720,000, a change of -19,309,000 (-538.0%).
- Net loss of 60,606,000 reduced equity.
- New share issuances of 29,200,000 increased equity.
- Other factors increased equity by 12,097,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.61 Million | -385.53% |
| Share Issuances | $29.20 Million | +185.75% |
| Other Changes | $12.10 Million | +76.95% |
| Total Change | $- | -538.01% |
Book Value vs Market Value Analysis
This analysis compares Oncology Institute Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.66 | $5.10 | x |
| 2020-12-31 | $0.48 | $5.10 | x |
| 2021-12-31 | $1.57 | $5.10 | x |
| 2022-12-31 | $1.53 | $5.10 | x |
| 2023-12-31 | $0.77 | $5.10 | x |
| 2024-12-31 | $0.05 | $5.10 | x |
| 2025-12-31 | $-0.02 | $5.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncology Institute Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.06%
- • Asset Turnover: 3.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-288.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -9.52% | -2.59% | 2.61x | 1.41x | $-8.24 Million |
| 2020 | -50.96% | -7.64% | 2.85x | 2.34x | $-17.13 Million |
| 2021 | -10.49% | -5.38% | 1.00x | 1.95x | $-21.34 Million |
| 2022 | 0.12% | 0.06% | 0.96x | 2.12x | $-12.17 Million |
| 2023 | -145.67% | -25.62% | 1.55x | 3.67x | $-88.77 Million |
| 2024 | -1801.70% | -16.44% | 2.28x | 48.12x | $-65.02 Million |
| 2025 | 0.00% | -12.06% | 3.05x | 0.00x | $-59.03 Million |
Industry Comparison
This section compares Oncology Institute Inc's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $441,613,417
- Average return on equity (ROE) among peers: 9102.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncology Institute Inc (TOI) | $-16.29 Million | -9.52% | N/A | $400.93 Million |
| Acadia Healthcare Company Inc (ACHC) | $432.55 Million | 4.72% | 1.27x | $1.52 Billion |
| Addus HomeCare Corporation (ADUS) | $34.58 Million | 11.64% | 2.93x | $1.69 Billion |
| agilon health Inc (AGL) | $661.02 Million | -39.73% | 1.63x | $264.44 Million |
| Airsculpt Technologies Inc (AIRS) | $79.29 Million | -10.41% | 1.65x | $354.84 Million |
| Amedisys Inc (AMED) | $879.72 Million | 12.80% | 0.48x | $3.32 Billion |
| AMN Healthcare Services Inc (AMN) | $284.13 Million | 12.09% | 1.26x | $624.22 Million |
| American Shared Hospital Service (AMS) | $11.83 Million | 169.54% | 1.28x | $8.87 Million |
| American Oncology Network Inc. (AONC) | $24.17K | 90834.23% | 1.03x | $292.48 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.52 Billion | 13.82% | 2.26x | $1.33 Billion |
| Astrana Health Inc (ASTH) | $510.64 Million | 13.50% | 0.70x | $1.90 Billion |
About Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as edu… Read more